实体瘤中[68Ga]Ga-pentixafor的CXCR4导向PET/CT:影像表现综合分析及与组织病理学的比较
本研究纳入142例23种经组织学证实的实体瘤患者,行[68Ga]Ga-pentixafor CXCR4导向PET/CT共152次扫描。103/152次(67.8%)扫描显示高于血池的摄取(TBR>1),共462个病灶。卵巢癌SUVmax最高,IRS与SUVmax呈弱但统计学显著相关(ρ=0.328;P=0.018)。
要点
- 103/152次(67.8%)扫描显示TBR>1的CXCR4摄取,共462个病灶(52个原发灶、410个转移灶)。
- 中位TBR为4.4(1.05-24.98),提示高图像对比度;卵巢癌SUVmax最高。
- 42/103次(40.8%)扫描记录到超过5个靶病灶,其中12/42次(28.6%)SUVmax高于10。
核心结论
- 全身肿瘤读出显示,相当一部分常见实体瘤表现出增高且均匀的[68Ga]Ga-pentixafor摄取,并伴高图像对比度。
- 观察到体内与体外CXCR4表达之间存在相应联系,提示该PET显像剂具有高特异性。
- 一部分[68Ga]Ga-pentixafor阳性肿瘤负荷患者被认为可能适合CXCR4导向治疗。
研究设计与样本
- 纳入142例经组织学证实的23种不同实体瘤患者,行CXCR4导向[68Ga]Ga-pentixafor PET/CT,共152次扫描。
- 对CXCR4阳性肿瘤负荷进行半定量分析,包括SUVmax和以血池为背景的靶/本底比(TBR)。
- 对患者肿瘤组织行组织病理学染色确定免疫反应评分(IRS),并分析其与SUVmax的相关性(Spearman ρ)。
- 基于影像评估CXCR4导向放射性配体治疗或非放射性CXCR4抑制治疗的适合性(定义为超过5个CXCR4高摄取靶病灶且SUVmax高于10)。
主要发现
- 103/152次(67.8%)扫描显示高于血池的摄取(TBR>1),共462个病灶(52个原发肿瘤、410个转移灶)。
- 中位TBR为4.4(1.05-24.98),提示高图像对比度。
- SUVmax最高见于卵巢癌,其次为小细胞肺癌、促结缔组织增生性小圆细胞肿瘤和肾上腺皮质癌。
- 全队列比较原发肿瘤与转移灶的放射性示踪剂积聚,SUVmax相当(P>0.999),但肺部病灶除外(P=0.013),提示靶病灶间CXCR4表达均匀。
- IRS较高时与SUVmax增高呈弱但统计学显著相关(ρ=0.328;P=0.018)。
关键数值与推荐
- CXCR4阳性摄取定义为TBR>1(高于血池)。
- CXCR4导向治疗适合性定义为超过5个CXCR4高摄取靶病灶且SUVmax高于10。
- IRS与SUVmax相关性:ρ=0.328;P=0.018。
- 原发灶与转移灶SUVmax比较:全队列P>0.999,肺部病灶P=0.013。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: C-X-C motif chemokine receptor 4 (CXCR4) is overexpressed in various solid cancers and can be targeted by CXCR4-directed molecular imaging. We aimed to characterize the in-vivo CXCR4 expression in patients affected with solid tumors, along with a comparison to ex-vivo findings. METHODS: A total 142 patients with 23 different histologically proven solid tumors were imaged with CXCR4-directed PET/CT using [68 Ga]Ga-pentixafor (total number of scans, 152). A semi-quantitative analysis of the CXCR4-positive tumor burden including maximum standardized uptake values (SUVmax) and target-to-background ratios (TBR) using blood pool was conducted. In addition, we performed histopathological staining to determine the immuno-reactive score (IRS) from patients' tumor tissue and investigated possible correlations with SUVmax (by providing Spearman's rho ρ). Based on imaging, we also assessed the eligibility for CXCR4-targeted radioligand therapy or non-radioactive CXCR4 inhibitory treatment (defined as more than five CXCR4-avid target lesions [TL] with SUVmax above 10). RESULTS: One hundred three of 152 (67.8%) scans showed discernible uptake above blood pool (TBR > 1) in 462 lesions (52 primary tumors and 410 metastases). Median TBR was 4.4 (1.05-24.98), thereby indicating high image contrast. The highest SUVmax was observed in ovarian cancer, followed by small cell lung cancer, desmoplastic small round cell tumor, and adrenocortical carcinoma. When comparing radiotracer accumulation between primary tumors and metastases for the entire cohort, comparable SUVmax was recorded (P > 0.999), except for pulmonal findings (P = 0.013), indicative for uniform CXCR4 expression among TL. For higher IRS, a weak, but statistically significant correlation with increased SUVmax was observed (ρ = 0.328; P = 0.018). In 42/103 (40.8%) scans, more than five TL were recorded, with 12/42 (28.6%) exhibiting SUVmax above 10, suggesting eligibility for CXCR4-targeted treatment in this subcohort. CONCLUSIONS: In a whole-body tumor read-out, a substantial portion of prevalent solid tumors demonstrated increased and uniform [68 Ga]Ga-pentixafor uptake, along with high image contrast. We also observed a respective link between in- and ex-vivo CXCR4 expression, suggesting high specificity of the PET agent. Last, a fraction of patients with [68 Ga]Ga-pentixafor-positive tumor burden were rendered potentially suitable for CXCR4-directed therapy.
引用
- Dreher N, Hahner S, Fuß CT, et al. CXCR4-directed PET/CT with [68 Ga]Ga-pentixafor in solid tumors-a comprehensive analysis of imaging findings and comparison with histopathology. Eur J Nucl Med Mol Imaging. 2023. PMID: 38082196. doi:10.1007/s00259-023-06547-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。